Grifols Stock - weekly outlook with earnings and debt focus
Published on 06/22/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 07:39 CET. Details in the imprint.
Grifols (ES0171996087) enters this week with markets still focused on its balance sheet, governance changes and the timeline for its next financial update. After a turbulent start to the year, the company remains under scrutiny from equity and credit investors.
Background and data on Grifols stock
Key figures, news and filings help investors track how Grifols addresses leverage, governance and earnings visibility.
What recent filings show
Grifols last reported quarterly results for the first quarter of 2024 on 04/30/2024, posting revenue of about EUR 1.66 billion and adjusted EBITDA of around EUR 501 million, according to its earnings release.
In that update, management reiterated its focus on deleveraging, targeting a reduction in net financial debt to EBITDA to below 4 times by 2025 from higher levels in prior years.
Weekly outlook and earnings calendar
The company has not yet published a firm date for its next interim results on the financial calendar of its investor relations site; the most recent entries reference the 2024 annual general meeting and past quarterly releases.
Against this backdrop, investors this week are likely to watch for any new corporate presentations, rating-agency updates or regulatory filings that could clarify progress on asset disposals and debt reduction.
How the company makes money
Grifols generates most of its revenue from plasma-derived medicines, collecting human plasma through a large network of donation centers and processing it into therapies such as immunoglobulins, albumin and coagulation factors for chronic and acute conditions.
Where the stock trades today
The shares of Grifols (ES0171996087) trade on the Spanish stock exchange BME in Madrid at EUR 10.00 as of 06/21/2026, 17:35 CET.
Key facts on Grifols stock
- Company: Grifols S.A.
- ISIN: ES0171996087
- WKN: A0PHG0
- Ticker: GRF
- Venue: BME Madrid
- Price (as of 06/21/2026, 17:35 CET): 10.00 EUR
- Market cap: 7,500,000,000 EUR (as of 06/21/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: IBEX 35
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
